Eurofarma
Eurofarma, officially known as Eurofarma Laboratórios S.A., is a prominent Brazilian pharmaceutical company headquartered in São Paulo, Brazil. Established in 1972, Eurofarma has grown to become a key player in the Latin American pharmaceutical industry, with a strong presence across various operational regions, including Central and South America. Specialising in the development, manufacturing, and marketing of prescription medicines, generics, and over-the-counter products, Eurofarma is recognised for its commitment to quality and innovation. The company’s diverse portfolio includes therapeutic areas such as oncology, cardiology, and central nervous system disorders, setting it apart with its focus on patient-centric solutions. With a robust market position, Eurofarma has achieved significant milestones, including numerous certifications and awards for excellence in pharmaceutical practices, reinforcing its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Eurofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofarma's score of 60 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eurofarma's reported carbon emissions
In 2023, Eurofarma reported total carbon emissions of approximately 41,604,000 kg CO2e. This figure includes 16,992,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 7,827,000 kg CO2e from Scope 2 emissions, related to the consumption of purchased electricity. Additionally, Scope 3 emissions totalled about 16,785,000 kg CO2e, which includes indirect emissions from the value chain. Eurofarma has made significant climate commitments, being the first Brazilian pharmaceutical company to publicly pledge to neutralise 100% of its direct CO2 emissions by 2030. This commitment extends to Scope 1 and Scope 2 emissions, with a long-term goal to achieve this by 2038. The company is also implementing strategies to ensure a 100% clean energy matrix, which will aid in the reduction of its Scope 2 emissions. In terms of reduction initiatives, Eurofarma's park in Bahia is projected to provide an average of 15.6 MWm, with an anticipated reduction of 260,000 tonnes of CO2 by 2038. This aligns with their broader strategy to mitigate climate impact and enhance sustainability within their operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 12,594,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,611,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eurofarma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
